Prospective, multicenter study to compare the curative effects of chemotherapy and haploidentical HSCT in first remission (CR1) for adult acute leukemia

Conditions

Adult acute leukemia

Yan N, Wang ZL, Wang XJ, Gale RP, Zhou YL, Zhao MY, Wu LX, Liao MY, Yang J, Wang CY, Zhu JH, Jiang H, Jiang Q, Liu YR, Chang YJ, Xu LP, Zhang XH, Ma TH, Huang XJ, Ruan GR.

2024-07-0410 citations

10.1016/j.canlet.2024.217104

Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.

Wu LX, Zhao MY, Yan N, Zhou YL, Cao LM, Qin YZ, Jiang Q, Xu LP, Zhang XH, Huang XJ, Jiang H, Ruan GR.

2024-03-282 citations

10.1007/s10238-023-01255-2

S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.

Zhang J, Lu WY, Zhang JM, Lu RQ, Wu LX, Qin YZ, Liu YR, Lai YY, Jiang H, Jiang Q, Jiang B, Xu LP, Zhang XH, Huang XJ, Ruan GR, Liu KY.

2019-03-2713 citations

10.1111/bjh.15878

Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors

Yu Wang, Wu Depei, Qifa Liu, Lan‐Ping Xu, Xiaohui Zhang et al. (6 authors)

Blood2015-12-032 citations

10.1182/blood.v126.23.62.62

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study

Yu Wang, Qifa Liu, Lan‐Ping Xu, Kai‐Yan Liu, Xiaohui Zhang et al. (9 authors)

Blood2015-05-05480 citations

10.1182/blood-2015-02-627786

Interventions

Group A:Chemotherapy

Group B:Haploidentical HSCT

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. AML and ALL diagnosed according to WHO criteria; 2. Age: 15-60 years old; 3. CR1 phase; 4. No HLA-matched sibling donor or URD; 5. Intermediate and poor risk patients with AML AND adult ALL (except for patients with t(15;17), t(8;21), inv(16)/t(16;16)); 6. Physical score 0~2 (WHO); 7. Sign the informed consent document.

Exclusion criteria

Exclusion criteria: 1. Secondary acute leukemia; 2. Contradiction of HSCT, e.g. uncontrolled active infection and severe cardiac, hepatic, renal and pulmonary disease; 3. Low- risk patients with AML (patients with t(15;17), t(8;21), inv(16)/t(16;16)); 4. Pregnant; 5. Mental disorder; 6. Complicated with outher carcinoma; 7. Cann't sign the informed consent document.

Design outcomes

Primary

Measure	Time frame
Overall survival;Disease-free survival;Relapse rate;	—

Secondary

Measure	Time frame
Infection rates;Immune reconstruction;	—

Countries

China

Contacts

Public ContactHuang Xiaojun

xjhrm@medmail.com.cn+86 13701389625

Outcome results

None listed